Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Methods Mol Biol ; 480: 11-29, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19085121

RESUMEN

DNA vector-based short hairpin RNA (shRNA) as a means of effecting RNA interference (RNAi) is a promising mechanism for the precise disruption of gene expression to achieve a therapeutic effect. The clinical usage of shRNA therapeutics in cancer is limited by obstacles related to effective delivery into the nuclei of target cancer cells. Significant pre-clinical data have been amassed about biodegradable and non-biodegradable polymeric delivery vehicles that are relevant for shRNA delivery into humans. Here, we will review some leading candidates for clinical usage with a focus on studies relating to their potential for usage in cancer shRNA therapeutics and discuss some of the advantages and disadvantages of using biodegradable and non-biodegradable delivery vehicles.


Asunto(s)
Neoplasias/terapia , Polímeros/metabolismo , ARN/uso terapéutico , Silenciador del Gen , Humanos , Interferencia de ARN
2.
Expert Rev Anticancer Ther ; 7(3): 373-82, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17338656

RESUMEN

The use of DNA vector-based short hairpin (sh)RNA for RNA interference shows promise as a precise means for the disruption of gene expression to achieve a therapeutic effect. The in vivo usage of shRNA therapeutics in cancer is limited by obstacles related to effective delivery into the nuclei of target cancer cells. Nonviral delivery vehicles that are relevant for shRNA delivery into humans belong to a group of substances about which significant preclinical data has been amassed to show an acceptable safety profile, resistance to immune defenses and good transfection efficiency. Here, we review the most promising current nonviral gene delivery vehicles with a focus on their potential use in cancer shRNA therapeutics.


Asunto(s)
Terapia Genética/métodos , Neoplasias/terapia , ARN Interferente Pequeño/administración & dosificación , Biopolímeros/administración & dosificación , Biopolímeros/farmacocinética , Cationes , Núcleo Celular/metabolismo , Sistemas de Liberación de Medicamentos , Endocitosis , Humanos , Ligandos , Liposomas/administración & dosificación , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/genética , Neoplasias/genética , Vehículos Farmacéuticos , Polímeros/administración & dosificación , Polímeros/farmacocinética , Interferencia de ARN , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/farmacocinética , ARN Interferente Pequeño/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA